Continuation of Long-Acting Bronchodilators During COPD Exacerbation
Rationale for Continuation
Long-acting bronchodilators provide sustained bronchodilation that remains beneficial even during COPD exacerbations 1, 2
LABA/LAMA combinations demonstrate superior efficacy in preventing subsequent exacerbations and improving patient-reported outcomes compared to single bronchodilators or LABA/ICS combinations, particularly in high-risk patients 1, 2
Discontinuing maintenance therapy during exacerbations increases the risk of prolonged recovery time and subsequent exacerbations 3
Stopping LABA/LAMA during exacerbations removes the foundation of bronchodilation and may worsen outcomes 1, 2
Acute Phase Management
Continue current LABA/LAMA maintenance therapy at the prescribed dose during COPD exacerbations 1, 2
Add short-acting bronchodilators (short-acting beta-agonists and/or short-acting muscarinic antagonists) for acute symptom relief during exacerbations 1
Initiate systemic corticosteroids for moderate to severe exacerbations 1
Consider antibiotics if there are signs of bacterial infection (increased sputum purulence, volume, or dyspnea) 1
Post-Exacerbation Therapy Escalation
For patients on LABA/LAMA who experienced an exacerbation with blood eosinophils ≥300 cells/μL or history of asthma-COPD overlap, escalate to LABA/LAMA/ICS triple therapy 1, 3
For patients with chronic bronchitis phenotype and FEV1 <50% predicted on LABA/LAMA who experienced an exacerbation, consider adding roflumilast 1, 4
For former smokers on LABA/LAMA with recurrent exacerbations, consider adding macrolide therapy (e.g., azithromycin), weighing risks of antimicrobial resistance and cardiac effects 1, 3, 4
For patients already on triple therapy (LABA/LAMA/ICS) who continue to exacerbate, add macrolide maintenance therapy if a former smoker, with moderate certainty of benefit in reducing exacerbation rates 3
For patients on triple therapy with chronic bronchitic phenotype who continue to exacerbate, add roflumilast 3, 4
Therapy De-escalation Considerations
- The Canadian Thoracic Society weakly recommends against stepping down from LABA/LAMA/ICS to LABA/LAMA in high-risk patients, as withdrawal may increase exacerbation risk, particularly in those with eosinophils ≥300 cells/μL 3
Phenotype-Specific Management
In patients with chronic bronchitis phenotype, roflumilast addition to LABA/LAMA reduces exacerbations in those with FEV1 <50% predicted and history of hospitalization for exacerbation 1, 4
Do not add ICS indiscriminately after exacerbations without considering eosinophil counts or asthma overlap, as ICS increases pneumonia risk without clear benefit in low-eosinophil patients 1
For low eosinophil phenotype patients with recurrent exacerbations, consider non-ICS add-on therapies (roflumilast, macrolides) 1
Evidence Quality
- The recommendation to continue LABA/LAMA during exacerbations is supported by Level A evidence from GOLD guidelines for long-acting bronchodilators as cornerstone therapy 1, 4
COPD Management with LABA/LAMA Combination Therapy
Initial Treatment Selection
- The American Thoracic Society recommends LABA/LAMA combination therapy as the preferred first-line treatment for COPD patients with high symptom burden (Group B) who have persistent breathlessness, and for all Group D patients due to superior efficacy in preventing exacerbations and improving patient-reported outcomes compared to single bronchodilators or LABA/ICS combinations 5, 6
- For Group B patients, the American College of Chest Physicians suggests starting with a single long-acting bronchodilator (LABA or LAMA) as initial therapy, and escalating to LABA/LAMA combination when patients have persistent breathlessness on monotherapy 5, 6, 7, 8
- The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend initiating LABA/LAMA combination as first-line therapy for Group D patients, based on superior patient-reported outcomes, prevention of exacerbations, and avoidance of pneumonia risk associated with inhaled corticosteroids 5, 6, 8, 9
Special Considerations
- The European Respiratory Society suggests reserving ICS-containing regimens for patients with asthma-COPD overlap, elevated blood eosinophil counts, or frequent exacerbations despite LABA/LAMA therapy 5, 6, 8
- For patients with persistent exacerbations on LABA/LAMA, the American College of Chest Physicians recommends considering escalation to triple therapy (LABA/LAMA/ICS) or switching to LABA/ICS and adding LAMA if necessary 5, 6, 8
Add-On Therapies
- The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest considering add-on therapies such as roflumilast for patients with severe chronic bronchitis and frequent exacerbations, or macrolide therapy for former smokers with frequent exacerbations 5, 6, 8